摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-{[(3-{1-[(cyclopropylmethyl)amino]-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl}-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl)oxy]methyl}-1,3-thiazole-4-carbonitrile | 691361-37-2

中文名称
——
中文别名
——
英文名称
2-{[(3-{1-[(cyclopropylmethyl)amino]-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl}-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl)oxy]methyl}-1,3-thiazole-4-carbonitrile
英文别名
2-[[3-[1-(cyclopropylmethylamino)-4-hydroxy-2-oxoquinolin-3-yl]-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazin-7-yl]oxymethyl]-1,3-thiazole-4-carbonitrile;2-[[3-[1-(cyclopropylmethylamino)-4-hydroxy-2-oxoquinolin-3-yl]-1,1-dioxo-4H-1λ6,2,4-benzothiadiazin-7-yl]oxymethyl]-1,3-thiazole-4-carbonitrile
2-{[(3-{1-[(cyclopropylmethyl)amino]-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl}-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl)oxy]methyl}-1,3-thiazole-4-carbonitrile化学式
CAS
691361-37-2
化学式
C25H20N6O5S2
mdl
——
分子量
548.603
InChiKey
ZKQDIEUHUMVSCB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    38
  • 可旋转键数:
    7
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    194
  • 氢给体数:
    3
  • 氢受体数:
    10

文献信息

  • Anti-infective agents
    申请人:——
    公开号:US20040162285A1
    公开(公告)日:2004-08-19
    Compounds having the formula 1 are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
    具有公式1的化合物是丙型肝炎病毒(HCV)聚合酶抑制剂。还公开了一种用于抑制丙型肝炎病毒(HCV)聚合酶的组成和方法,用于制造这些化合物的过程,以及在这些过程中使用的合成中间体。
  • ANTI-INFECTIVE AGENTS
    申请人:ABBOTT LABORATORIES
    公开号:EP1560827B1
    公开(公告)日:2010-12-29
  • US7902203B2
    申请人:——
    公开号:US7902203B2
    公开(公告)日:2011-03-08
  • [EN] ANTI-INFECTIVE AGENTS<br/>[FR] AGENTS ANTI-INFECTIEUX
    申请人:ABBOTT LAB
    公开号:WO2004041818A1
    公开(公告)日:2004-05-21
    The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HCV) polymerase, a method for inhibiting HCV viral replication, and a method for treating or preventing HCV infection. Processes for making said compounds, and synthetic intermediates employed in said processes, are also provided.
查看更多